Christopher Timmermann
Co-director of the UCL Centre for Consciousness Research
Data updated
Research Footprint
Christopher Timmermann appears in 54 tracked papers (2018–2026), most studied alongside DMT, Psilocybin and LSD, across Neuroimaging & Brain Measures, Depressive Disorders and Healthy Volunteers.
Most-cited paper: Increased global integration in the brain after psilocybin therapy for depression (425 citations).
Frequent co-authors: Robin Carhart-Harris, David Nutt and Leor Roseman.
Publication Landscape
How the 54 papers Blossom tracks for Christopher Timmermann line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Christopher Timmermann's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 54 of 54 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Christopher Timmermann publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Christopher Timmermann publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Christopher Timmermann is a neuroscientist and psychologist focusing on the mechanisms of psychedelics on the brain and mind. Having led the DMT Research Group at Imperial College London, he now co-directs the UCL Centre for Consciousness Research. His work uses EEG and fMRI to map the 'DMT state' and explores the intersection of psychedelics, meditation, and human consciousness.
Key Impact
Leading the vanguard of research into DMT and its profound effects on human consciousness and neural dynamics.
Collaboration Network
89 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Christopher Timmermann's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Christopher Timmermann is associated with.
Imperial College London
academicHead, Psychedelics Research Group
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →University College London
academicThe Understanding Neuroplasticity Induced by Tryptamines (UNITY) Project was launched at University College London. UNITY represents the first-in-human study of psychedelics at UCL. The team utilizes techniques such as fMRI, eye-tracking and experience sampling to enhance our understanding of the neurobiological mechanisms predicting cognitive and mental health outcomes following psychedelic use, initially investigating the effects of DMT.
View stakeholder →